Difference between revisions of "Avandia"
(→Links to heart attack risks) |
(→Links to heart attack risks) |
||
| Line 9: | Line 9: | ||
==Links to heart attack risks== | ==Links to heart attack risks== | ||
| − | After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating '''Avandia''''s manufacturer, [[GlaxoSmithKline]], knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. <ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> The senate asked the [[FDA]] to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.<ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> Two FDA officials Food and Drug Administration are recommending the drug is pulled from the market.<ref>Harris, G. ''The New York Times''[http://www.nytimes.com/2010/02/20/health/policy/20avandia.html Research Ties Diabetes Drug to Heart Woes] Accessed 23 February 2010.</ref> | + | After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating '''Avandia''''s manufacturer, [[GlaxoSmithKline]], knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. <ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> The senate asked the [[FDA]] to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.<ref>The Washington Post (Associated Press). 21 February 2010. [http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks] Accessed 23 February 2010.</ref> Two FDA officials Food and Drug Administration are recommending the drug is pulled from the market.<ref>Harris, G. ''The New York Times'' [http://www.nytimes.com/2010/02/20/health/policy/20avandia.html Research Ties Diabetes Drug to Heart Woes] Accessed 23 February 2010.</ref> |
==Notes== | ==Notes== | ||
<references/> | <references/> | ||
Revision as of 23:20, 23 February 2010
|
This article is part of the Pharma_Portal project of Spinwatch. |
Background
Avandia or Rosiglitazone, is one of GlaxoSmithKline's blockbuster drugs for type 2 diabetes. It was raking in 4.6 million pounds a day in the early months of 2007, when an independent researcher who worked at the Cleveland Clinic in America, Steven Nissen, published a controversial meta-analysis of the drug in the New England Journal of Medicine (NEJM). Nissen added up heart problem data in all the previously published studies of Avandia in order to examine the drug’s safety profile. He concluded that users are 43 per cent more likely to have heart attacks and that there is an even higher increase in the risk of fatal heart problems.[1]
In April 2008, The Scotsman reported on NHS Scotland's reaction to Nissen's meta-analysis: Doctors Demand Freeze on use of diabetes drug for heart patients
Links to heart attack risks
After a two year inquiry, the US Senate Finance Committee issued a report in February 2010 stating Avandia's manufacturer, GlaxoSmithKline, knew of possible heart attack risks tied to its drug and 'tried to play down findings that the drug could increase cardiovascular risks while also working to minimize findings that a rival medication might reduce such risks'. [2] The senate asked the FDA to explain 'why it allowed a clinical trial of Avandia to continue even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007'.[3] Two FDA officials Food and Drug Administration are recommending the drug is pulled from the market.[4]
Notes
- ↑ Nissen, S., and Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. The New England Journal of Medicine, volume 356:2457-2471.
- ↑ The Washington Post (Associated Press). 21 February 2010. Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks Accessed 23 February 2010.
- ↑ The Washington Post (Associated Press). 21 February 2010. Senate report ties GlaxoSmithKline diabetes drug Avandia to heart attack risks Accessed 23 February 2010.
- ↑ Harris, G. The New York Times Research Ties Diabetes Drug to Heart Woes Accessed 23 February 2010.
